Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC...

Area of Science:

• Neuro-oncology
• Clinical trial analysis
• Cancer genomics

Background:

• A prior trial demonstrated temozolomide plus radiotherapy improved survival in newly diagnosed glioblastoma.
• This study aimed to identify new prognostic factors and develop predictive models using existing trial data.

Purpose of the Study:

• To confirm or identify prognostic factors for glioblastoma survival.
• To derive nomograms for predicting individual patient prognosis.
• To suggest stratification factors for future clinical trials.

Main Methods:

• Subanalysis of 573 patients from the EORTC/NCIC trial (26981-22981/CE.3).
• Survival modeling using Cox proportional hazards models, with and without O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status.
• Development of nomograms to predict median and 2-year survival probabilities.

Main Results:

• Independent prognostic factors for improved survival included: temozolomide treatment, more extensive tumor resection, younger age, Mini-Mental State Examination (MMSE) score ≥27, and no baseline corticosteroid use.
• MGMT promoter methylation status, age, performance status, extent of resection, and MMSE score were significant in specific patient subgroups.
• Predictive nomograms integrating these factors are available online.

Conclusions:

• MGMT promoter methylation status, age, performance status, extent of resection, and MMSE are recommended as eligibility or stratification factors for future glioblastoma trials.
• Mandatory stratification by MGMT promoter methylation status is advised for trials using alkylating chemotherapy.
• Nomograms facilitate individualized patient management by predicting prognosis with molecular insights.